Providing precision diagnostics and the possibility of immediate treatment initiation results in a significant positive impact on the cost and burden of healthcare and opens tremendous perspectives for the improvement of the diagnosis of sepsis and its timely, optimal clinical management, for the benefit of patients.
Abionic, a developer of disruptive nanotechnology-based rapid diagnostic solutions recently announced (13th September 2019) the successful completion of its international pivotal study using Abionic’s novel point-of-care Pancreatic Stone Protein (PSP) sepsis test on the abioSCOPE® platform. The results of the study show anticipation of 24 hours for the diagnosis of sepsis compared to current standard of care and offers results in just 5 minutes with a drop of capillary blood for the earliest detection of sepsis, this enables physicians to make critical decisions at the point of need.
Dr Nicolas Durand, CEO Abionic, will present how Abionic’s new technology disrupts Point of Care Diagnostics bringing value to patients and helping health care practitioners make the right decision at the right time, whilst cutting the overall burden on healthcare at the IPC on 28th October at 02:10 PM